Help Your Patients
Experience Growth

Boy and girl discuss soccer.

A Clinical Commitment

SKYTROFA® has been studied in over 300 children with GHD, including treatment‑naïve and treatment-experienced patients1‑3

SKYTROFA phase 3 program in pediatric GHD1‑4

Chart of Skytropha Phase 3 Program

Experience Growth

Once-weekly SKYTROFA: Demonstrated higher LS mean AHV at week 52 in treatment-naïve children compared with a daily somatropin1,2

LS mean AHV and height SDS changes from baseline at week 52: Once-weekly SKYTROFA versus daily somatropin1,2*

* At week 52, patients receiving once-weekly SKYTROFA had an LS mean (SE) AHV of 11.2 (0.2) cm/year compared with 10.3 (0.3) cm/year for those receiving a daily somatropin, and a change from baseline in height SDS LS mean (SE) of 1.10 (0.04) compared with 0.96 (0.05).1,2
  • The treatment difference in LS mean AHV with SKYTROFA compared with daily somatropin was 0.9 cm/year1,2
    • 95% CI of 0.2 to 1.5 cm/year1,2
    • The weekly dose of hGH was equivalent to 0.24 mg hGH/kg/week for both SKYTROFA and daily somatropin1
  • The change in mean (SD) bone age from baseline to week 52 was similar with SKYTROFA (1.36 [0.87] years) and daily somatropin (1.35 [0.72] years)5

Sustained growth was achieved with SKYTROFA in treatment-naïve patients6

Patients treated with SKYTROFA had a greater increase from baseline in height SDS compared with patients treated with a daily somatropin2‡

LS mean by ANCOVA.2
Patients treated with SKYTROFA and daily somatropin had an increase in height SDS from baseline (SE) of 1.10 (0.04) and 0.96 (0.05) at week 52, respectively. Estimated difference = 0.14 SDS.2

Once-weekly SKYTROFA makes dosing easy for patients and their healthcare professionals